EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified — Trials · CancerIndex

Clinical trials

Registered studies

20 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 13
Recruiting: 5
Ph III recruiting: 0
Growth YoY: —
Industry share: 15%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04231877	Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma	active not recruiting	Phase 1	56	University of WashingtonOTHER	1	Sep 29, 2026	clinicaltrials
NCT06544265	SynKIR-310 for Relapsed/Refractory B-NHL	recruiting	Phase 1	36	Verismo TherapeuticsINDUSTRY	1	Apr 14, 2026	clinicaltrials